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Climate change has the potential to increase the threat of water-borne diseases, through rises in
temperature and sea-level, and precipitation variability. Cholera poses a particular threat, and the
need to develop better intervention tools is imminent. Cholera infections are particularly severe
for blood group O individuals, who are less protected by the current vaccines. Here we derive a
hypothesis as to the molecular origins of blood-group dependence of this disease, based on relevant
epidemiological, clinical and molecular data, and give suggestions on how to plan prevention strat-
egies, and develop novel and improved pharmaceuticals.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Cholera – disease and treatment
Exposure to the bacterial pathogen Vibrio cholerae through con-
taminated drinking water or food products, such as undercooked
seafood, can lead to cholera (reviewed by [1]), a severe and often
fatal diarrheal disease. Cholera is endemic to the Ganges Delta
and since the 19th century has spread from India to the rest of
the world through several pandemics. The current (seventh) pan-
demic started in Indonesia in 1961, and is mainly a result of the
more recent V. cholerae serogroup O1 biotype, known as El Tor.
Outbreaks typically occur in waves, usually during the warmer sea-
son after heavy rainfalls. During cooler periods of the year, the
pathogen retracts to its water reservoirs, where it is associated to
zooplankton and phytoplankton, either as free-swimming cells or
in bioﬁlms [2–7].
Since 2005, cholera outbreaks have become notably more dra-
matic. According to the World Health Organization (WHO) [8],
237 000 cases were reported in 2006, from 52 countries. This re-chemical Societies. Published by E
in B pentamer; ETEC, enter-
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otoxin B pentamer of human
gel).sulted in 6300 deaths, which represents an increase of 79% com-
pared to 2005. One of the world’s largest outbreaks ever recorded
occurred just one year ago in Zimbabwe and neighboring countries,
with very high fatality rates observed (up to 6% in treatment facil-
ities and 62% in the community at large) [9,10]). These statistics are
still believed to be underestimates as underreporting is common.
More realistic estimates suggest that in reality, several million peo-
ple fall ill from cholera every year, resulting in hundreds of thou-
sands deaths, mostly in Africa [10,11], but also in Asia [12,13].
There are many factors involved in V. cholerae virulence, but the
key agent responsible for the severe diarrhea is the cholera toxin
(CT), which is secreted from vibrios co-expressing a bacteriophage
[14,15]. CT belongs to the AB5 family of toxins [16], and consists of
one catalytic A subunit (CTA), which is anchored to a ring of ﬁve B
subunits (CTB, cholera toxin B pentamer) (Fig. 1). The B subunits
are responsible for interacting with epithelial cell surface receptors
in the small intestine of the human host, while the A subunit is
responsible for the toxic effects. After entering the cell through
endocytosis, cholera toxin hijacks the cell’s endogenous pathways
[17]. This is how the A subunit gains access to the cytosol, where it
is refolded and exerts its action by ADP-ribosylating Gsa, which in
turn activates adenylate cyclase, leading to constitutively in-
creased cAMP levels [18]. Ultimately, this leads to the opening of
ion channels and the outpour of electrolytes and water into the
intestinal lumen. Fluid loss can be greater than one liter per hour,
which can lead to death as a result of severe dehydration.lsevier B.V. All rights reserved.
Fig. 1. Cartoon representation of cholera holotoxin (PDB entry 1S5E [109]), with
carbohydrate ligand superimposed (from PDB entry 3CHB [110]). (a) The catalytic A
subunit (yellow) is anchored in the center of the receptor-binding B pentamer. The
pentasaccharides bound to the bottom of the B pentamer are representative of the
primary cell surface receptor (GM1) on the epithelial cells of the small intestine. (b)
View perpendicular to (a) showing the B pentamer, looking down onto the
membrane surface (ﬁgure generated with PyMOL [111]).
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erly applied, usually reduces fatality rates from >20% as seen his-
torically to <1% (WHO) [19]. In addition, an internationally
licensed oral cholera vaccine is available, consisting of killed V.
cholerae in combination with CTB (Dukoral). This vaccine is 85–
90% effective after half a year [20–22] and retains ca. 50% protec-
tive efﬁcacy after 3 years [23]. It also provides herd immunity
[24,25].
2. Blood-group dependence of infectious diseases
The susceptibility to cholera depends on a number of factors,
including local intestinal immunity (from previous exposure or
vaccination), bacterial load and intrinsic host factors, such as stom-ach pH (gastric acid provides a barrier) and blood group (reviewed
by [1]). In this review we focus speciﬁcally on the role of blood-
group antigens on the infection process.
The blood group of an individual is determined by the presence
or absence of inherited antigenic substances on the surface of the
red blood cells. Perhaps the most well-known blood-group anti-
gens are the ABH antigens, which are speciﬁc carbohydrates con-
stituting terminal structures of glycan chains on glycolipids and
glycoproteins (Fig. 2). The term ‘blood group antigen’ is potentially
misleading, as these antigens are also abundant in body ﬂuids and
tissues, such as the gut, and therefore should rather be referred to
as ‘histo-blood-group antigens’ (although we use the terms inter-
changeably). Of the ABH antigens, the H antigen is the shortest
and characterized by a terminal fucose residue, whereas the A
and B antigens each contain one additional saccharide residue –
a terminal 20-N-acetyl galactosamine (GalNAc) in the A antigen,
or a terminal galactose for the blood group B antigen.
Epidemiological studies as early as the 1970s identiﬁed that
individuals with blood group O (carrying the unmodiﬁed H anti-
gen) were more susceptible to severe cholera (cholera gravis) than
other individuals [26,27]. Since then multiple case-control studies
have demonstrated that people with blood group O are at in-
creased risk of hospitalization due to V. cholerae O1 El Tor as well
as V. cholerae O139 [28–33]. On the other hand, for infection with
classical V. cholerae strains, no such association was found [34],
suggesting that blood-group dependence is strain speciﬁc.
Although cholera serves as a prominent example of the correla-
tion between blood group type and disease, such an association has
been observed in many other infectious diseases of bacterial, viral
and parasitic origin, such as plague, smallpox, and mumps [35],
although the correlation is not always as clear as for cholera. Peo-
ple of the blood group O phenotype are indeed more likely to be-
come infected with Norwalk viruses (while blood group B
individuals appear to have a lower disease incidence) [36] and a re-
cent study on mosquito borne dengue infections showed that chil-
dren with this blood type may similarly be predisposed to severe
dengue hemorrhagic fever [37]. However, blood group O individu-
als are not always at the highest risk of contracting the more severe
disease, but rather the consequences of blood type for disease out-
come vary, both between diseases, and even between different
pathogenic strains. Blood-group antigens may also have the ability
to confer protection against certain diseases, as has been recently
observed for malaria [38–40] and HIV infections [41].
Indeed, there is increasing evidence that bacterial and viral
infections are among the selective forces acting on blood-group
antigens to produce, and conserve, the human blood group poly-
morphism [42–45]. For the human population at large, such a poly-
morphism is beneﬁcial, as it helps create a barrier to diseases, and
prevents the eradication of entire populations, at the expense of
individuals with the susceptible blood type to a given disease.
Currently, information as to the molecular basis of blood-group
dependence of infectious diseases is relatively limited, a statement
that holds true for microbial recognition of human surface glyco-
conjugates in general [46]. Microbes may utilize host surface anti-
gens during many different stages of the infection process, such as
colonization and elaboration of virulence factors. The origin of
blood-group dependence has mainly been attributed to the inter-
action of toxins, adhesins or viral capsid proteins with the glycoca-
lyx covering the host cell surface.
An example of one such relationship that has been characterized
at themolecular level is the Norovirus, causing epidemic diarrhea in
humans (also known as ‘winter vomiting disease’). The processes
underlying the genogroup-speciﬁc interaction of the viral capsid
with different antigens of the ABH histo-blood group system has re-
cently been elucidated using high-resolution X-ray crystallographic
analysis of the capsid P domains [47,48]. Genogroup I noroviruses
Fig. 2. Schematic drawing of the blood group A type 2 pentasaccharide GalNAca3(Fuca2)Galb4(Fuca3)GlcNAcb. The reducing end of the blood-group antigen is shown
(unconventionally) on the left, for consistency with Fig. 3. The GalNAca3 residue (in bold), characteristic of blood group A antigens, is substituted by a galactose in blood
group B antigens, and is absent in blood group H antigens characteristic for blood group O (ﬁgure generated with ChemDraw).
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type blood-group antigens, where the capsid is optimally struc-
tured to accommodate the terminal Gal–Fuc (D-galactose–L-fucose)
residues (i.e. the H determinant of blood group O individuals) or,
alternatively, the GalNAc residue characteristic of blood group A
antigens. The genogroup II noroviruses exhibit amore diverse blood
group binding pattern, since they primarily recognize the terminal
fucose, which is common to all blood-group antigens.
3. Hypothesis: molecular basis of cholera blood-group
dependence
The blood-group dependence of cholera has been known for
more than three decades, namely that blood group O individuals
are more likely to become severely ill [28–33], although paradox-
ically they are less likely to be infected [32,33]. This ﬁnding holds
true for the recent El Tor cholera and for cholera O139 Bengal, but
not for classical cholera [34]. The molecular basis of these ﬁndings
is still unresolved.
Current models of cholera pathogenesis are characterized by
two key steps; colonization of the intestine (which includes muco-
sal adherence of the vibrios), and the elaboration of a potent
enterotoxin, i.e. the cholera toxin, which causes the secretory diar-
rhea. Since no correlation between blood group phenotype and cul-
ture-proven infection has been observed [28,29], the primary steps
of infection, i.e. mucosal adherence of vibrios, have been ruled out
as the cause of blood-group dependence, pointing to the impor-
tance of the later stages of pathogenesis, in particular the action
of the cholera toxin [32].
In order to test the hypothesis that the cholera toxin is respon-
sible for the blood-group dependence, numerous studies have been
conducted to investigate the ability of the cholera toxin and the
highly homologous heat-labile enterotoxin (LT), from enterotoxi-
genic Escherichia coli (ETEC), to recognize blood-group antigens of
the ABH system [49–54]. LT has indeed been shown to preferably
bind A and B active glycoconjugates over H active glycoconjugates
[51–53], while for cholera toxin the available evidence is some-
what contradictory; the general consensus appears to be that chol-
era toxin does not bind to blood-group antigens. However, this
belief has more recently been challenged, as increasing evidence
suggests that the cholera toxin is indeed responsible for blood
group recognition [55,56]. One important clue came from the studyof a chimera between the B subunits of cholera toxin and the E. coli
LT. This CTB/LTB chimera was shown to bind blood group A or B
antigens on type 2 chains [54], and was subsequently character-
ized in complex with a blood group A analog using protein crystal-
lography [55] (Fig. 3). A follow-up study showed that native LTB,
despite binding blood-group antigens with lower afﬁnity, also dis-
plays the same mode of binding as the CTB/LTB chimera [56].
Based on the two crystal structures, it was possible to explain
how the toxins discriminate between different ABH epitopes. The
GalNAca3 residue characteristic of blood group A antigens binds
to the toxin via several hydrogen bonds, including one involving
its acetamido nitrogen (Fig. 3c). The blood group B antigen is char-
acterized by a terminal galactose residue and only differs from the
A antigen at the 2-position, i.e. the acetamido group is replaced by
a hydroxyl group. This hydroxyl group should preserve most of the
interactions with the toxin and explains why the toxin does not
discriminate notably between A and B epitopes. The fucosyl resi-
due of the H antigen, a precursor of the A and B antigens, is also
an important contributor to receptor recognition, however, blood
group H determinants lack the entire terminal saccharide residue
compared to blood group A and B determinants, and would there-
fore be expected to have signiﬁcantly reduced binding afﬁnities to
cholera toxin. This assumption is substantiated by the ﬁnding that
the loss of a single water-mediated hydrogen bond to the terminal
GalNAca3 residue (Fig. 3c) results in a pronounced decrease in
binding afﬁnity [55], conﬁrming the importance of the terminal
GalNAc residue characteristic of blood group A antigens in molec-
ular recognition.
The architecture of the newly discovered binding site for blood-
group antigens strongly suggests that CTB has the potential to bind
to such ligands, despite the fact that CTB is generally acknowl-
edged as not recognizing these epitopes. This quandary may be ex-
plained by the fact that most binding studies to date utilize toxins
originating from the classical biotype of serogroup O1, which does
not show blood-group dependence. The El Tor cholera toxin (and
cholera toxin O139 Bengal) differ from the classical cholera toxin
at two biotype-speciﬁc residues in the B subunit, namely positions
18 and 47, both within the blood group binding site (Fig. 3c). While
Tyr18 and Ile47 are typical of the El Tor biotype, His18 and Thr47
are characteristic of the classical biotype [57,58]. Of the two resi-
dues, Tyr18 is likely to be more important for blood-group antigen
binding. This residue is also conserved in LTB, where it is found to
Fig. 3. (a) Surface representation of the B pentamer of the CTB/LTB chimera (PDB entry 3EFX [55]). The blood group A pentasaccharide analog Gal-
NAca3(Fuca2)Galb4(Fuca3)Glcb is shown as black sticks, with the GM1 pentasaccharide (cyan) superimposed for comparison. (b) Cartoon representation of the same
model, with only two subunits shown. Color-coding: conserved residues of the two subunits in grey/orange, residues speciﬁc to classical CTB in red, LTB-speciﬁc residues in
blue. (c) Detailed stereo-picture of the blood-group antigen binding site. Hydrogen bonds are indicated by dashed lines; the water-mediated hydrogen bond to GalNAca3,
characteristic of the CTB/LTB chimera, and absent in LTB, is shown as black dashed lines. Water molecules are represented by green spheres. The color-coding is as in (b). A
selection of residues is labelled (italic labels are used for the sugar residues). which is followed by as indicated, the corresponding CTB residues (red labels) are Asp7, His18
(classical CTB; ElTor: Tyr18) and His94, the corresponding LTB residue (blue label) is Ser4# from a neighboring subunit of the B pentamer. In CTB of the ElTor biotype
(serogroup O1) and of serogroup O139, Thr47 is replaced by Ile47. Note that Tyr18 (the second discriminatory residue of CTB El Tor and CTB O139, which is also found in LTB)
coordinates a water network, which is likely of signiﬁcant importance for blood group antigen binding. This residue is substituted by the shorter His18 in CTB of classical V.
cholerae strains, which does not contain this water network, or show blood group dependence (ﬁgure generated with PyMOL [111]).
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[55]. The crystal complexes of LTB and the CTB/LTB chimera with
the blood group ligands both contain this water network, which
is positioned at the reducing end of the sugar ligand [55,56]
(Fig. 3c). This water network is absent in the crystal structures of
classical CTB, which contain the shorter histidine residue at posi-
tion 18. Strongly bound water molecules can be considered an
extension of the protein surface, and are known to be important
contributors to ligand binding, especially for carbohydrates [59–
61]. The presence of Tyr18 in the El Tor biotype (serogroup O1),and the more recently discovered serogroup O139, suggests that
the architecture of the blood group binding site is essentially main-
tained [56], explaining the clear blood-group dependence of the
current cholera pandemic.
4. Biological implications of blood-group antigen binding?
The secretory diarrhea typical of cholera infections originates
from the human small intestine where the cholera toxin
binds to its primary receptor, i.e. the GM1 ganglioside [62]. The
2552 Å. Holmner et al. / FEBS Letters 584 (2010) 2548–2555gastrointestinal epithelium is extremely rich in glycoconjugates
and expresses, in addition to GM1, glycolipids and glycoproteins
that carry blood group ABH antigens [63–65]. In individuals
belonging to the secretor phenotype (ca. 80% of the population),
these blood-group antigens are also present on the mucus layer
lining the epithelial cells. Hence, for blood group A, B or AB individ-
uals, the cholera toxin could potentially bind to blood-group anti-
gens at the site of infection, reducing intoxication via the GM1-
route. This could help explain why people of blood group A, B
and AB phenotypes experience milder symptoms than individuals
only expressing the weaker-binding H antigen, i.e. people with
blood group O. In fact, it has recently been shown that pre-incuba-
tion of the B subunits of the CTB/LTB chimera with blood-group
antigens reduced the afﬁnity of the B subunits for GM1 and vice
versa [66], lending support to this hypothesis. Protection from se-
vere infection is particularly strong for secretors, who generally
experience milder symptoms than non-secretors [67], which can
be explained by a further protective effect conferred by their con-
tinuously shedding mucus layer. In addition to the physical re-
moval of the toxin due to the shedding mucus, the mucosal
secretions participate in the innate and adaptive immune protec-
tion against mucosal pathogens [68,69].
It is worth noting that in the related E. coli LT, the blood group A
active glycoconjugates on polarized intestinal-epithelial cells ap-
pear to act as functional receptors [70], promoting increases in
cAMP concentration. This is in apparent contradiction to the blood
group protection hypothesis, however, it is not clear if the capabil-
ity to stimulate cAMP production is equivalent to toxicity. In this
respect, the study by Guidry et al. is of signiﬁcant interest, who
demonstrated that an LT variant lacking GM1-binding properties
(LT-G33D) was non-toxic in vivo, while retaining the capability to
stimulate intracellular cAMP levels in vitro in Caco-2 intestinal-epi-
thelial cells [71]. Similar studies using CT-G33D have also been
undertaken [72]. This could mean that the GM1-route is essential
for toxicity and alternative routes do not induce diarrhea. Although
further study is certainly required to gain a full understanding of
the underlying molecular mechanisms, it is likely that secretors,
who constitute the majority of the population, will still experience
a protective effect if they carry blood group A or B antigens rather
than H antigens on their mucosal surfaces.
5. Cholera in the time of climate change
While cheap and effective medication for cholera is available in
the form of rehydration therapy, cholera outbreaks can be gener-
ally avoided in the ﬁrst place by providing clean drinking water
and good sanitation. Unfortunately, these basic requirements are
lacking in many parts of the world, and climate change is expected
to further aggravate this situation [73]. In many regions, the quan-
tity and quality of drinking water, and sanitation, are expected to
change, for the worse. This is likely to make prevention and inter-
vention of cholera a more costly and difﬁcult matter. For example,
one of the expected projections of climate change is the increased
risk of ﬂooding in tropical Asia [73], which could lead to the break-
down of sanitary conditions, promoting secondary cholera trans-
mission through the more direct fecal–oral route. Similar
consequences are expected from the projected increase in hurri-
canes and other storms [74]. In addition, intense rainfall has been
shown to result in more nutrients, pathogens, and toxins being
washed into water bodies, effectively contaminating the drinking
water [75–77].
The marine and coastal ecosystems are likely to be affected by
climate change in terms of sea-level rise and temperature increase.
Because vibrios reside in aqueous environments, an increase in sea
surface temperature favors pathogen growth and proliferation, e.g.through algal or zooplankton blooms [2]. This has the potential to
further aggravate cholera epidemics in coastal areas as well as near
lakes and rivers, which are primary sources of food and drinking
water.
It has long been assumed that climate variability has the ability
to directly inﬂuence the outbreaks of infectious diseases, such as
cholera, malaria and dengue fever. Numerous studies exist on the
subject, and increasing evidence is accumulating that such a corre-
lation indeed exists [78–84], including a long-term study on El Tor
cholera in Matlab, Bangladesh that spans a period of four decades
[85].
6. Targeted prevention and intervention strategies?
The mechanism by which blood group inﬂuences susceptibility
to cholera infections still requires further investigation, neverthe-
less the association is signiﬁcantly important to public health.
The disease has spread from its endemic areas around the world,
and in the light of climate change it is important to identify sensi-
tive groups for the development of directed intervention strategies.
Populations in cholera-endemic regions are somewhat pro-
tected due to previous exposure and acquired immunity [32,33,
86–88], and potentially through natural selection. For example,
in the Ganges Delta, the prevalence of blood group O is extremely
low, which has been attributed to recurring cholera epidemics [28].
However, for countries that have had little historical exposure to
cholera, the consequences of an outbreak will be more dire, and
populations where blood group O is predominant, such as the
natives of Latin America, are especially at risk. In such a setting,
cholera symptoms are more severe and the requirements for
hospitalization and rehydration therapy are substantially higher
[19,29]. Similar causes may lie at the heart of the recent severe out-
breaks in Africa, where typically ca. 50% of the population have
blood group O [44,89]. To eradicate the pathogen is virtually
impossible, since V. cholerae can easily survive outside the human
host in aquatic environments. Cholera outbreaks could in principle
be prevented by efﬁcient mass vaccinations; however, there are
several drawbacks, such as the limited time of protective immunity
conferred, the need for cold-chain distribution of the vaccine, its
short shelf life, as well as the requirement for a booster dose for
increased protection. The relatively high costs (ca. 7–12 US $ per
dose) present an additional hurdle, although a signiﬁcantly cheap-
er oral killed whole cell vaccine has recently been produced in
Vietnam [90] and several new candidate vaccines are in the pipe-
line [91]. So far it has been general policy not to use vaccination
as an intervention tool when outbreaks have already started, on
the assumption that outbreaks are self-limited and short-lived.
However, recent outbreaks have challenged this assumption
[10,20].
There are calls to change vaccination policies and provide oral
vaccines in addition to other life-saving interventions to contain
cholera outbreaks [10,92]. New vaccination strategies should also
consider information as to the blood-group dependence of the dis-
ease, mindful that individuals with blood group O are at the high-
est risk for severe symptoms, and as a result of this, most likely to
be hyperinfectious when ill [32,33,93,94]. Furthermore, while
blood group O individuals are somewhat less likely to be infected
compared to the rest of the population [32,33], they experience re-
duced protection upon vaccination [34]. This provides a strong
argument for the development of improved vaccines that confer
protection also to this target group.
The current internationally licensed cholera vaccine contains, in
addition to killed whole cell vibrios of both classical and El Tor bio-
types, the cholera toxin B subunit. This additive boosts short-term
protection against V. cholerae infection [95], acting as a potent
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nogenicity, and to some extent the adjuvanticity, are dependent on
receptor binding, as shown by the LT-G33D and CT-G33D variants,
which are devoid of GM1-binding activity [97–99]. It is possible
that also the binding to other receptors, especially if on the muco-
sa, contribute positively to CTB-induced immunogenicity. The fact
that blood group O individuals are less protected by vaccination
suggests that this may indeed be the case. Therefore, potential
shortfalls in vaccination efﬁcacies might be counteracted using as
vaccine components cholera toxin B subunits that are specially
engineered to maximize ligand afﬁnities. In this sense, chimera
of cholera toxin and E. coli heat-labile enterotoxin B subunits,
which have enhanced binding afﬁnities to human blood-group
antigens [54,55], seem to represent a good starting point. Such chi-
mera may in addition provide increased cross-protection against
ETEC infections [100–102] helping further relieve the burden of
infectious diarrheal diseases. Preferably such a chimera should re-
tain as many CTB-speciﬁc residues as possible. The El Tor-speciﬁc-
residue Tyr18 appears especially important in this respect, since it
has been shown to be important for blood-group antigen binding
in the published crystal structures [55,56] (Fig. 3c). The additional
inclusion of the second El Tor-speciﬁc-residue, Ile47, in the CTB
vaccine additive may confer even better protection against El Tor
cholera. At present, the vaccine contains recombinant classical
CTB (Personal communication, N. Carlin, SBL Vaccines, Sweden),
and appears to provide somewhat better protection against classi-
cal cholera than against El Tor cholera [23], despite containing
killed vibrios of both these biotypes.
It is likely, however, that even the most optimized CTB/LTB chi-
mera will bind more strongly to blood group A and B antigens com-
pared to the H antigens, leaving blood group O individuals
comparatively less protected. This is in the nature of the molecular
interactions, which are weaker if part of the interaction surface is
missing, as is the case for the H antigens. Epidemiological models
predict that 50% vaccination coverage in endemic areas provide
89% reduction in cholera cases among the unvaccinated and 93%
reduction overall in the population [25] and suggest that 70% cov-
erage would probably be necessary for cholera control of popula-
tions with less natural immunity. However, these models do not
take into account that the blood group O risk group is less preva-
lent in the endemic areas on which the predictions are based. Fu-
ture epidemiological models should account for this, and
evaluate if it would be advantageous to especially select this
high-risk group for vaccination. This could be especially important
for young children that are not breast fed.
Another strategy to quickly curb the development of severe out-
breaks may be the employment of more effective medicinal drugs.
Although initially more expensive than rehydration therapy, their
application could relieve the pressure on hospital resources and,
more importantly, help to reduce the spread of an epidemic. Cur-
rently, rehydration therapy is generally recommended in combina-
tion with antibiotics. However, with the increasing occurrence of
multiple-antibiotic-resistant V. cholerae strains [103], the develop-
ment of new pharmacological agents that inactivate cholera toxin
is of signiﬁcant value. Drugs that inhibit the interaction of the chol-
era toxin with its primary receptor, the GM1 ganglioside, are espe-
cially attractive. These pharmaceuticals have the added advantage
that drug resistance may be avoided, since the cholera toxin is se-
creted rather than associated with the bacterial pathogen. Recent
trends in this respect are the development of non-hydrolysable
GM1 mimics [104] and multi-valent GM1 derivatives [105–108].
The new information on the molecular recognition of blood-group
antigens by diarrheal toxins presented here should enable medici-
nal chemists to develop improved drug design strategies. These
could then be given in combination with rehydration therapy to
blood group O patients and, possibly, to non-secretors, to optimizeavailable resources. The application of improved vaccines, vaccina-
tion strategies and medicinal drugs together are likely to have a
signiﬁcant impact on the containment of severe cholera epidemics.
7. Summary
The uprooting of large populations, and the breakdown of infra-
structures, associated with natural disasters and aggravated by cli-
mate change, provide ideal grounds for cholera. As a result, cholera
and other water-borne diseases pose an increasing threat to people
already living at the margins of survival, where populations with a
high prevalence of blood group O are especially at risk. The analysis
of cholera toxin-related structures in complexes with a blood
group determinant suggests how cholera toxin discriminates be-
tween blood-group antigens, which may help to explain the ob-
served blood-group dependence of V. cholerae infections. Such
data can now be used to inform and plan prevention and interven-
tion strategies, as discussed.
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